Controlled Flares and Progressive Damage — Why Partial Control Is Not Enough

The Inter-Episode Interval Is Not Neutral

Patients who have achieved partial control of HS through suppressive treatment often describe the periods between flares as a kind of normalcy — not comfortable, not without awareness of the condition, but manageable. Compared to the acute phase of a flare, the inter-episode interval feels like relief. This is accurate as a subjective experience. It is not accurate as a biological description of what is happening internally during that interval.

The inter-episode interval in partially controlled HS is not a period of biological neutrality. The internal drivers of HS — gut-derived inflammatory signalling, hormonal dysregulation, immune irregularity, metabolic imbalance — continue operating at their characteristic level throughout this period. Suppressive treatment reduces the peak expression of these drivers — the acute flare — but does not address the drivers themselves. Between flares, those drivers are still producing their effects on the internal environment: sustaining low-grade systemic inflammation, maintaining the hormonal conditions that favour follicular occlusion, preserving the immune state that responds disproportionately when occlusion occurs.

The consequence is that the inter-episode interval, while relatively calm externally, is a period of continued internal disease activity — and continued accumulation of the subclinical damage that this activity produces.

Three Forms of Damage That Accumulate Between Episodes

The damage that accumulates in partially controlled HS between acute flares takes three distinct forms, each with different clinical consequences and different implications for treatment.

Incremental Tissue Remodelling

Each inflammatory episode in HS — including low-grade, sub-clinical inflammatory activity that does not reach the threshold of a visible flare — produces some degree of tissue remodelling in affected areas. The inflammatory mediators that are active during and between episodes stimulate fibroblast activity, promote collagen deposition, and progressively alter the architecture of the dermis and subcutaneous tissue in repeatedly affected regions.

This remodelling is cumulative and incremental. A patient whose flares have been reduced from monthly to quarterly has not reduced the tissue remodelling process by 75% — they have reduced the most acute phase of it. The low-grade inflammatory activity persisting between those quarterly flares continues to remodel tissue throughout the inter-episode interval. Over years of partially controlled disease, the cumulative tissue change that results from this ongoing remodelling determines how much structural damage has accumulated regardless of whether individual flares were frequent or rare.

This is why patients with long-standing HS who have achieved reasonable flare control often notice, over years, a gradual worsening in the character of affected areas — increased firmness, reduced skin mobility, development of scarring that was not present in earlier stages — even though they feel the condition is "under control." The control is of the acute peaks, not of the process that is incrementally remodelling the tissue between those peaks.

Progressive Immune Regulatory Depletion

The immune regulatory capacity that is progressively depleted in long-standing HS does not recover during inter-episode intervals if the internal environment sustaining chronic immune activation remains unchanged. The regulatory immune cells and signalling pathways that should moderate inflammatory responses operate in a state of ongoing demand even between flares, because the gut-derived inflammatory signals, hormonal influences, and metabolic factors that require regulatory management are continuously present.

Each period of sustained immune activation — whether it manifests as a visible flare or as the sub-clinical activation between flares — depletes regulatory capacity incrementally. Partial flare control reduces the peak regulatory demand but does not eliminate the continuous baseline demand that is progressively exhausting the regulatory system. Over years of partially controlled disease, the regulatory capacity that remains is less than it was at the start of control — not because of the acute flares that occurred, but because of the continuous sub-clinical activation that persisted between them.

This progressive regulatory depletion explains a pattern many patients recognise: treatment that was once reliably effective at controlling flares becomes less effective over time, even though nothing in the treatment has changed. The treatment has not become less effective — the regulatory capacity that the treatment was supporting has been progressively reduced by the ongoing sub-clinical disease activity that the treatment was not addressing.

Systemic Inflammatory Burden Accumulation

Chronic systemic inflammation — sustained at even moderate levels over years — produces effects on organ systems and metabolic function that extend well beyond the skin. Cardiovascular risk, insulin sensitivity, metabolic function, mood regulation, and cognitive clarity are all influenced by the sustained systemic inflammatory state that partially controlled HS maintains.

These systemic effects accumulate across the full duration of the disease, not just during acute flares. A patient who has had partially controlled HS for ten years has been exposed to ten years of elevated systemic inflammatory burden — in the form of chronically elevated inflammatory markers, altered metabolic signalling, and the hormonal consequences of sustained inflammation — regardless of how many or how few visible flares occurred in that decade. The systemic consequences of this sustained burden are not reversed by flare control; they are only prevented by the reduction of the underlying inflammatory state that generates them.

What Partial Control Misses — And Why It Matters

The clinical significance of inter-episode damage accumulation becomes clear when patients with long-standing partially controlled HS are evaluated against patients whose HS was treated with a root-cause approach from an earlier stage. The partially controlled patients consistently show more accumulated tissue damage, lower immune regulatory capacity, and more extensive systemic inflammatory consequences — despite having had comparable or even fewer acute flares — because the internal environment driving damage was not corrected, only its peak expression was reduced.

This is not an argument against flare control as a treatment objective. Reducing flare frequency and severity genuinely reduces suffering and quality of life impairment. It is an argument that flare control should not be the endpoint of treatment — that the objective of treatment should be correction of the internal environment that generates flares, not management of the flares themselves.

When internal correction is achieved — when gut function is restored, hormonal balance is established, immune regulation is rebuilt, and metabolic function is normalised — flares do not simply reduce in frequency. The internal environment that generates them is changed, and the sub-clinical disease activity that was persisting between flares is also reduced. This is a qualitatively different outcome from flare suppression, and it is the only outcome that stops the incremental accumulation of damage during the inter-episode interval.

Recognising the Trajectory — Before the Damage Becomes Definitive

The practical value of understanding inter-episode damage accumulation is recognising, as early as possible in the disease trajectory, that partial control is a transitional state rather than a satisfactory endpoint — and that the longer it is sustained, the more difficult correction becomes, because the accumulated damage raises the threshold that treatment must overcome.

Patients who achieve partial control and remain in that state for years are not stable. They are on a gradual trajectory of accumulated tissue damage, depleting immune regulatory capacity, and increasing systemic inflammatory burden — all occurring at a pace that is too slow to be clearly visible from year to year but produces significant cumulative change over the course of five to ten years of partially controlled disease.

Recognising this trajectory while there is still time to alter it — while the tissue damage is not yet advanced, while the immune regulatory capacity is still substantially intact, while the systemic inflammatory consequences have not yet produced secondary conditions — is the most important reason to pursue internal correction rather than accepting flare management as the final goal. Earlier intervention against the internal drivers produces better outcomes not because the treatment works differently at earlier stages, but because the degree of accumulated damage that needs to be reversed is less, and the biological capacity for correction is greater.